Biotest Value Stock - Dividend - Research Selection
Market price: 29,10 EUR
Biotest AG Vz Fundamental data and company key figures of the share
|Annual reports in EUR|
|Net operating cash flow||-16.700.000|
|Free cash flow||-43.700.000|
|Liabilities & Shareholders equity||1.131.300.000|
|Diluted shares outstanding||39.571.500|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||1.406.240.128,00 USD|
|Indices||CDAX,Prime All Share|
|Raw Data Source||IFRS in Millionen EUR|
|Stock Split||2015-07-15,3.0000/1.0000; 2013-06-12,477.000000/476.000000; 2005-10-13,641.000000/619.000000; 1997-06-13,735.000000/694.000000; 1996-09-02,10.000000/1.000000; 1994-09-01,845.000000/816.000000|
Description of the company
Biotest AG is a Germany-based international supplier of biological medications. It diversifies its activities into three business segments: Therapy segment, Plasma and Services segment, as well as Other segment. Its Therapy segment comprises the development and production of blood plasma-based immunoglobulin clotting factors and albumins, which are used in diseases of the immune system, hematological diseases, and intensive care medicine. It also includes the preclinical and clinical development of monoclonal antibodies, indications for which include rheumatoid arthritis and blood cancer. Furthermore, the Companys Plasma and Services segment includes the areas of plasma sales and toll manufacturing. Its Other segment, includes retail business and costs that cannot be allocated to the Therapy segment or the Plasma and Services segment.